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ABSTRACT
The WNT signaling pathway has an essential role in colorectal carcinogenesis and progression, which
involves a cascade of genetic and epigenetic changes. We aimed to analyze DNA methylation
affecting the WNT pathway genes in colorectal carcinogenesis in promoter and gene body regions
using whole methylome analysis in 9 colorectal cancer, 15 adenoma, and 6 normal tumor adjacent
tissue (NAT) samples by methyl capture sequencing. Functional methylation was confirmed on 5-aza-
20-deoxycytidine-treated colorectal cancer cell line datasets. In parallel with the DNA methylation
analysis, mutations of WNT pathway genes (APC, b-catenin/CTNNB1) were analyzed by 454
sequencing on GS Junior platform. Most differentially methylated CpG sites were localized in gene
body regions (95% of WNT pathway genes). In the promoter regions, 33 of the 160 analyzed WNT
pathway genes were differentially methylated in colorectal cancer vs. normal, including
hypermethylated AXIN2, CHP1, PRICKLE1, SFRP1, SFRP2, SOX17, and hypomethylated CACYBP, CTNNB1,
MYC; 44 genes in adenoma vs. NAT; and 41 genes in colorectal cancer vs. adenoma comparisons.
Hypermethylation of AXIN2, DKK1, VANGL1, and WNT5A gene promoters was higher, while those of
SOX17, PRICKLE1, DAAM2, and MYC was lower in colon carcinoma compared to adenoma. Inverse
correlation between expression and methylation was confirmed in 23 genes, including APC, CHP1,
PRICKLE1, PSEN1, and SFRP1. Differential methylation affected both canonical and noncanonical WNT
pathway genes in colorectal normal-adenoma-carcinoma sequence. Aberrant DNA methylation
appears already in adenomas as an early event of colorectal carcinogenesis.
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Introduction
Colorectal cancer (CRC) is one of the most frequent cancers
world-wide with an annual incidence of approximately
1 300 000 newly diagnosed cases, and a very high global mortal-
ity of more than 690 000/year.1 Although more and more CRC-
associated molecular alterations are determined, epidemiologi-
cal data emphasize the necessity of further research of this dis-
ease. CRC can develop through several distinct molecular
pathways (adenoma-carcinoma sequence, serrated neoplastic
pathway or on the basis of long-standing inflammatory bowel
disease) involving a cascade of genetic, epigenetic events affect-
ing gene expression changes.2-4 The analysis of these pathways
can improve our understanding of colorectal carcinogenesis
and can reveal potential diagnostic, prognostic, and therapeutic
predictive markers.
Abnormalities of epigenetic regulation such as DNA methyl-
ation alterations can contribute to malignant transition.5-6 It is
well known that global hypomethylation and promoter
hypermethylation of several tumor suppressor genes are
characteristic in cancers.7 Furthermore, with the advent of
whole methylome analysis, several studies allude to the impor-
tant role of methylation alterations in the transcribed regions
of genes (gene body region)7 with a remarkable proportion of
differentially methylated CpG sites located there5-6 and influ-
encing the regulation of gene expression.8-9
The WNT signaling pathway (Table 1, Supplementary
Table 1) has an essential role in colorectal carcinogenesis
and progression, which is characterized by accumulation of
genetic and epigenetic changes. The most known WNT path-
way alterations, such as APC and AXIN2 inactivation by
mutations or loss of heterozygosity, affect the APC-GSK3-
Axin complex leading to b-catenin stabilization, thereby
resulting in the constitutive activation of canonical WNT sig-
naling in CRC.10 Promoter hypermethylation of negative reg-
ulators of canonical WNT pathway like secreted frizzled-
related proteins (SFRPs),11-18 dickkopf family proteins
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(DKKs),11,17,19-21 and WIF1 WNT inhibitory factor11,17,21 has
also been described in malignancies, including CRC. Methyl-
ation patterns of CRC and normal adjacent tissue samples
were compared in most of the previous global methylation
studies focusing on WNT signaling pathway.20,22 Colorectal
adenoma samples were involved in methylation analyses for
selected WNT pathway genes11,15,17,23,24 focusing mainly on
promoter methylation level alterations. Serrated adenoma
samples—representing another neoplastic pathway of CRC
development—were also profiled in several previous methyl-
ation projects.23,25-27
Illumina BeadChip technology is a frequently used method
in global methylation studies22,28,29 and allows the determina-
tion of the methylation status of >485,000 CpG sites at single-
nucleotide resolution. Next generation sequencing of the
methylated DNA regions, such as methyl capture sequencing
(MethylCap-seq), is another option for genome-wide methyla-
tion analysis for revealing novel differentially methylated
regions (DMRs).30,31 MethylCap-seq provides a more extensive
overview of whole-genome methylation than BeadChip methyl-
ation arrays; however, it has lower resolution and sensitivity.31
In this study, we aimed to analyze the most frequent
genetic and global DNA methylation alterations of WNT
pathway genes in parallel during colorectal normal-ade-
noma-carcinoma sequence progression. We tested both pro-
moter and gene body DNA methylation alterations using
MethylCap-seq and studied the potential regulatory role of
the identified DMRs on mRNA expression of WNT signaling
pathway genes. Approximately 15-20% of CRCs belong to
the distinct molecular subtype of cancers called CpG island
methylator phenotype (CIMP) with high degree of DNA
methylation of certain genes (CIMP-high).7 However, the
DNA methylation changes also affect CIMP-negative
(CIMP-zero or CIMP-low) CRCs, which represent the
majority (approximately 75%) of sporadic CRCs.7,17 In this
study, we focused on CIMP-negative CRCs and their precan-
cerous lesions in order to find common DNA methylation
alterations of WNT pathway genes typical in development
and progression of sporadic colorectal cancer.
Results
Determination of microsatellite instability (MSI) and CpG
island methylation phenotype (CIMP) status
According to the results of immunohistochemical staining for
MMR genes (MLH1, MSH2, MSH6, PMS2), all samples were
found to be microsatellite stable (MSS). Using dichotomized
CIMP status determination [CIMP-negative (CIMP-zero or
CIMP-low) or CIMP-positive (CIMP-high)], all tumor samples
were proven to be CIMP-negative, according to both classic7,32
and Weisenberger CIMP status panel.33
DNA methylator analysis of WNT signaling pathway genes
Methylation status of 160 WNT pathway-related genes (Gene
symbols shown in Table 1 and detailed gene information
shown in Supplementary Table 1) was analyzed at 100 bp reso-
lution in 30 colorectal tissue samples [9 colorectal cancer
(CRC), 15 adenoma (AD), 6 normal adjacent tissue (NAT)] by
MethylCap-seq (Table 2 and Table 3).
Methylated CpG containing DNA fragments were effectively
isolated using MethylCap protein (Supplementary Figure 1A).
Recovery was 12.51 § 10.14% in methyl-captured DNA sam-
ples, while the unmethylated fraction was slightly detected
(0.41 § 0.16%). Sequencing results of all samples fulfilled the
quality criteria, according to the MEDIPS quality control proto-
col.34 Pearson correlation coefficient of saturation analysis
exceeded the 0.5 threshold for every sample (0.71 § 0.07).
Coverage of at least 5% of the methylation sites (11.43 §
2.56%) was more than 5 times for each sample during the CpG
coverage analysis. According to the CpG enrichment test, the
efficacy of the methyl capture was proven to be appropriate as
all samples showed value well above the 1.4 threshold (enrich-
ment score relH: 2.87§ 0.42) (Supplementary Figure 1B, C, D).
During the determination of DMRs both in promoter and in
gene body regions, methylation changes were considered signif-
icant if P-values were under 0.05 and at least a 10% methylation
difference could be measured (absolute value of Db was > 0.1).
Table 1. Analyzed WNT pathway genes.
WNT pathway Gene symbol
Canonical pathway AES, AKT1, AKT2, AKT3, APC, APC2, AXIN1, AXIN2, BAMBI, BTRC, CACYBP, CCND1, CCND2, CCND3, CER1,
CHD8, CREBBP, CTBP1, CTBP2, CTNNB1, CTNNBIP1, CUL1, CXXC4, CSNK1A1, CSNK1A1L, CSNK1E, CSNK2A1,
CSNK2A2, CSNK2B, DKK1, DKK2, DKK4, DVL1, DVL2, DVL3, EP300, FBXW11, FOSL1, FRAT1, FRAT2, FZD1,
FZD10, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, GSK3B, JUN, LEF1, LRP5, LRP6, MAP3K7, MMP7,
MYC, NKD1, NKD2, NLK, PORCN, PPARD, PPP2CA, PPP2CB, PPP2R1A, PPP2R1B, PPP2R5A, PPP2R5B, PPP2R5C,
PPP2R5D, PPP2R5E, PRKACA, PRKACB, PRKACG, PRKX, PSEN1, RBX1, RUVBL1, SENP2, SFRP1, SFRP2, SFRP4,
SFRP5, SIAH1, SKP1, SMAD2, SMAD3, SMAD4, SOX17, TBL1X, TBL1XR1, TBL1Y, TCF7, TCF7L1, TCF7L2, TLE1,
TLE2, TLE3, TLE4, TLE6, TP53, WIF1, WNT1, WNT10A, WNT10B, WNT11, WNT16, WNT2, WNT2B, WNT3, WNT4,
WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B
Planar cell polarity pathway DAAM1, DAAM2, DVL1, DVL2, DVL3, FZD1, FZD10, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8, FZD9, GPC4,
MAPK10, MAPK8, MAPK9, NKD1, NKD2, PRICKLE1, PRICKLE2, RAC1, RAC2, RAC3, RHOA, ROCK1, ROCK2,
VANGL1, VANGL2, WNT11,WNT5A
WNT/Ca2C pathway CAMK2A, CAMK2B, CAMK2D, CAMK2D, CHP1, CHP2, FZD1, FZD10, FZD2, FZD3, FZD4, FZD5, FZD6, FZD7, FZD8,
FZD9, NFAT5, NFATC1, NFATC2, NFATC3, NFATC4, PLCB1, PLCB2, PLCB3, PLCB4, PPP3CA, PPP3CB, PPP3CC,
PPP3R1, PPP3R2, PRKCA, PRKCB, PRKCG,WNT5A, WNT5B
Official gene symbols of WNT pathway genes according to KEGG WNT signaling map. Detailed data for these genes can be seen in Supplementary Table 1.
 WNT signaling pathway genes in other intracellular pathways, such as PI3K-AKT, TGFB, P53, and MAPK signaling. Genes with differentially methylated promoters in CRC
vs. NAT comparison are indicated in bold; genes with differentially methylated promoters in adenoma vs. NAT comparison are underlined.
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The promoter regions of 33 out of the 160 analyzed WNT
pathway genes were differentially methylated in CRC compared
to NAT, including hypermethylated AXIN2, CHP1, PRICKLE1,
SFRP1, SFRP2, SOX17, and hypomethylated CACYBP, CTNNB1,
MYC (Fig. 1A, Table 1). In AD vs. NAT comparison, altered pro-
moter methylation of 44 WNT signaling genes was detected,
including hypermethylated APC, AXIN2, DAAM2, DKK4,
PRICKLE1, SOX17, SFRP1, SFRP2 and SFRP4, and hypomethy-
lated CACYBP, FZD3 (Fig. 1B, Table 1). Forty-one genes were
identified showing different promoter methylation levels between
CRC and AD samples. Hypermethylation of AXIN2, DKK1,
VANGL1, and WNT5A gene promoters was increased in CRC
compared to AD, while promoter methylation of SOX17,
PRICKLE1, DAAM2, and MYC genes was higher in AD than
in CRC (Fig. 1C). The whole gene list, including genomic
positions and P- and b-values for DMRs, is shown in Supplemen-
tary Table 2A (CRC vs. NAT), 2B (AD vs. NAT), and 2C (CRC
vs. AD).
Promoter methylation alterations have been firstly men-
tioned, since their effect on gene expression is well described,
but most of the detected differentially methylated CpG sites
were localized in gene body regions. In CRC samples, 93.75%
(150 out of 160) of the analyzed WNT pathway genes had
DMRs in their gene body region (all together, 3788 DMRs). In
the adenoma group, a similar proportion (96.88%) of WNT
pathway genes showed aberrant gene body methylation, with
approximately 1.5-fold higher number of DMRs (total of 5737
DMRs).
In silico DNA methylation analysis of WNT pathway genes
CpG sites belonging to the significant DMRs in our Methyl-
Cap-sey study were searched using the Illumina BeadChip
450K array data sets from Luo et al.28 (GEO accession number:
GSE48684; Table 3) and P- and Db-values were determined in
CRC vs. NAT, AD vs. NAT, and CRC vs. AD comparisons.
Approximately one third of significant promoter DMRs
detected by MethylCap-seq were represented in the Illumina
BeadChip 450K data set by at least one cg ID (one CpG site;
Table 4). Within the represented regions, 58% of the promoter
methylation changes could be validated between CRC and
NAT samples, 83% between AD and NAT samples, and 30% in
CRC vs. AD comparison. In the case of gene body alterations,
only approximately 3% of significant DMRs obtained by
Table 2. Clinical data of colorectal tissue samples used in MethylCap-seq study.
Sample
ID
Patient
ID Sex Age Localization Histology TNM Grade
Dukes’
stage
Adenoma
size
Normal adjacent tissue
MCS_20090930_0001_01_100 1 M 74 rectum normal adjacent tissue (from
adenoma patient 1)
MCS_20110000_0019_01_100 19 F 76 rectum normal adjacent tissue (from CRC
patient 19)
T3N0M0 G2 B2
MCS_20061114 _0020_01_100 20 M 72 coecum normal adjacent tissue (from CRC
patient 20)
T3N0M0 unknown B2
MCS_20061113 _0021_01_100 21 M 68 sigma normal adjacent tissue (from CRC
patient 21)
T3N0M0 unknown B2
MCS_20110000_0022_01_100 22 M 58 sigma normal adjacent tissue (from CRC
patient 22)
T3N0M0 G2 B2
MCS_20110000_0023_01_100 23 F 68 sigma and rectum normal adjacent tissue (from CRC
patient 23)
T4N0M0 G1 B3
Adenoma
MCS_20100222_0004_01_210 4 M 78 rectum adenoma with low-grade dysplasia 25 mm
MCS_20100427_0005_01_210 5 M 65 rectum adenoma with low-grade dysplasia 25 mm
MCS_20100609_0007_01_210 7 M 66 rectum adenoma with low-grade dysplasia 20 mm
MCS_20110310_0012_01_210 12 M 83 sigma adenoma with low-grade dysplasia 35mm
MCS_20110914_0013_01_210 13 M 55 colon desc, sigma adenoma with low-grade dysplasia 10 mm
MCS_20120109_0014_01_211 14 M 81 sigma adenoma with low-grade dysplasia 5 mm
MCS_20120308_0015_01_211 15 M 48 colon transv adenoma with low-grade dysplasia 5 mm
MCS_20120320_0016_01_211 16 M 58 sigma adenoma with low-grade dysplasia 15 mm
MCS_20120801_0017_01_211 17 F 56 colon asc, transv adenoma with low-grade dysplasia 8 mm
MCS_20091104_0002_01_220 2 M 60 rectum-sigma adenoma with high-grade dysplasia 15 mm
MCS_20100610_0006_01_220 6 M 68 colon desc adenoma with high-grade dysplasia 5 mm
MCS_20100810_0008_01_220 8 M 73 sigma adenoma with high-grade dysplasia 8 mm
MCS_20100923_0009_01_220 9 M 74 rectum adenoma with high-grade dysplasia 8 mm
MCS_20110111_0010_01_220 10 M 68 colon desc adenoma with high-grade dysplasia 15 mm
MCS_20110203_0011_01_220 11 F 76 colon desc adenoma with high-grade dysplasia 20 mm
Colorectal cancer
MCS_20110203_0011_02_312 11 F 76 rectum adenocarcinoma T2N0M0 G2 B1
MCS_20110310_0012_02_312 12 M 83 coecum-colon asc adenocarcinoma T2N0M0 G2 B1
MCS_20061114 _0020_02_310 20 M 72 coecum adenocarcinoma T3N0M0 unknown B2
MCS_20061113 _0021_02_310 21 M 68 sigma adenocarcinoma T3N0M0 unknown B2
MCS_20110000_0023_02_311 23 F 68 sigma and rectum adenocarcinoma T4N0M0 G1 B3
MCS_20100201_0003_01_320 3 M 68 sigma-rectum inoperablof CpG sitee CRC with
multiplex metastases
unknown unknown D
MCS_20100610_0006_02_322 6 M 68 colon desc adenocarcinoma T3N2Mx G2 D
MCS_20110111_0010_02_322 10 M 68 rectum adenocarcinoma T2N2M0 G2 C2
MCS_20110914_0013_02_322 13 M 55 rectum adenocarcinoma T3N1M0 G2 C2
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MethylCap-seq were represented in the BeadChip 450K array,
and 25–51% of the methylation alterations could be confirmed
between the diagnostic groups (Table 4).
Gene expression analysis of WNT signaling pathway genes
Gene expression data of colonic tissue samples from the Gene
Expression Omnibus (GEO) database were involved in in silico
mRNA expression analysis of 160 WNT pathway genes (GEO
accession numbers: GSE37364,35 GSE8671,36 GSE18105,37
GSE32323,38 GSE22242,39 GSE9348)40 (Table 3). The log Fold
Change (logFC) data of significantly differentially expressed
WNT pathway genes, together with the methylation data, are
shown in Supplementary Table 2 for AD vs. NAT, CRC vs.
NAT, and CRC vs. AD comparisons. Compared to promoter
methylation alterations, the expression of 10 WNT signaling
genes, including CACYBP, CTNNB1, MYC, PRICKLE1, PSEN1,
and SFRP1, changed oppositely in CRC vs. NAT comparison
(Table 5). The expression of 14 WNT pathway genes, including
APC, CHP1, DAAM2, PRICKLE1, RUVBL1, SFRP1, SFRP2,
SFRP4, and TLE3, were inversely correlated with promoter
methylation status in AD vs. NAT samples (Table 6). In CRC
vs. AD tissues, the expression of 8 genes, including CTNNB1,
CXXC4, PRICKLE1, VANGL1, and SFRP2, was opposed to pro-
moter methylation differences (Table 7). Inverse relation
between promoter methylation and gene expression was found
in CACYBP, CHP1, CTNNB1, CXXC4, PRICKLE1, SFRP1,
SFRP2, and TLE3 genes, at least in 2 of the 3 comparisons
(CRC vs. NAT, AD vs. NAT, and CRC vs. AD).
Demethylation analysis on colon cancer cell lines
Gene expression data of 5 5-aza-20-deoxycytidine-treated colon
cancer cell lines were evaluated (GEO accession numbers:
GSE29060,41 GSE32323,38 GSE14526,42 and GSE4158843)
(Table 3).
Upregulation of mRNA expression was observed—at least in
one of the analyzed colon cancer cell lines after 5-aza-20-deoxycyti-
dine demethylation treatment—for 7 genes (APC, CHP1,
PRICKLE1, PRKCB, PSEN1, SFRP1, and TLE3) showing promoter
hypermethylation and downregulatedmRNA expression in benign
and/or malignant colonic tissue samples. In SW480 and HCT116
colorectal adenocarcinoma cell lines, 86–100% of the genes showed
opposite expression changes caused by the demethylation treat-
ment (Fig. 2). GSE29060 and GSE41588 data sets were also evalu-
ated, but mRNA expression of the above-mentioned genes was not
restored in HT29 cell line by the demethylating treatment.
APC and b-catenin mutation analysis
Mutation analysis of APC and b-catenin genes was performed
on the same sample set that was used in the whole methylome
profiling. APC mutations were detected in 0% of NAT, 27% of
adenoma, and 29% of CRC samples, while none of the samples
showed b-catenin mutation. Two truncated protein resulting in
frameshift mutations (COSM13113 and COSM296347) and 2
nonsense mutations with G/T substitution (COSM18775 and
COSM18759) were detected. A SNP with G/A substitution
(SNPrs41115) was found in 53% of adenoma samples and in
Figure 1. Differentially methylated regions in WNT pathway gene promoters.
Methylation probabilities (b-values) of 100 bp long analyzed regions were cal-
culated with respect to genome wide CpG density dependent Poisson distri-
butions, and are represented on a 0–1 scale. Promoter DMRs are shown A. in
colorectal cancer (CRC) vs. normal adjacent tissue (NAT) comparison B. in ade-
noma (AD) vs. NAT comparison and C. between CRC vs. AD samples. Methyla-
tion intensities are illustrated on a color scale: high methylation levels are
marked with red, low methylation levels are represented by green. Gene sym-
bols mentioned in the text are listed on the heat maps, the whole gene lists
with genomic positions, P- and b-values of DMRs can be seen in Supplemen-
tary Table 2.
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71% of CRC samples at the targeted APC sequence region. The
list and details of the detected mutations can be seen in Table 8.
Discussion
Similarly to other malignancies, colorectal cancer arises as a conse-
quence of accumulating genetic and epigenetic alterations. Beside
the conventional mutations, altered DNA methylation has also
been revealed as a causative factor in carcinogenesis and tumor
progression. Gene silencing mediated by aberrant promoter DNA
methylation is one of the key features of carcinogenesis.8 Gene
body regions are also strongly methylated, which can positively
correlate with the gene expression.8,9 The importance of DNA
methylation is further enhanced by the recently initiated trials
using low-dose DNA demethylating agents as anticancer drugs.9
We focused on DNA methylation analysis of WNT signaling
genes/gene promoters in CIMP-negative CRCs and precancer-
ous adenomas. Although since the establishment of CIMP con-
ception the main focus has been on DNA methylation analysis
of CIMP-positive proximal colon cancers, notable epigenetic
Table 4. Comparison of BeadChip 450K28 data and MethylCap-seq results for WNT pathway genes.
Comparison
Number
of DMRs by
MethylCap-seq
Number of
DMRs represented
in BeadChip 450K
Percentage
(rate) of DMRs
represented on BeadChip 450K
Number of
correspondingly changed
DMRs (represented on BeadChip 450K )
Percentage
(rate) of correspondingly
changed DMRs
PROMOTER
CRC vs. NAT 58 19 33% (19/58) 11 58% (11/19)
AD vs. NAT 129 47 36% (47/129) 39 83% (39/47)
CRC vs. AD 77 20 26% (20/77) 6 30% (6/20)
GENE BODY
CRC vs. NAT 3788 115 3.04% (115/3788) 30 26% (30/115)
AD vs. NAT 5737 167 2.91% (167/5737) 85 51% (85/167)
CRC vs. AD 4286 106 2.47% (106/4286) 26 25% (26/106)
Represented DMRs indicate the 100-bp-long differentially methylated regions detected by our MethylCap-seq study which are represented by at least one Illumina Bead-
Chip 450K cg ID (CpG site). Correspondingly changed DMRs indicate differentially methylated regions represented on both analyses that were found to be concordant
(similarly hyper- or hypo-methylated in the given comparison).
Table 5. WNT pathway genes showing inverse relation between DNA methylation and mRNA expression (CRC vs. NAT).
Gene expression
Gene data DNA methylation LogFC
Gene symbol Chr Start position P-value Db (CRC vs. NAT) Affymetrix probe set ID GSE37364 GSE18105/ GSE32323 GSE22242 GSE9348
CACYBP 1 174967901 0.0289 ¡0.44 201381_x_at 0.41 0.52 0.34 0.72
201382_at ¡0.23
210691_s_at 0.79 0.97 0.36 0.86
211761_s_at 0.35 0.52 0.65 1.01
CHP1 15 41524201 0.0348 0.39 207993_s_at ¡1.02 ¡1.67 ¡1.98 ¡2.36
214665_s_at ¡1.01 ¡1.44 ¡1.65
CTNNB1 3 41239901 0.0230 ¡0.38 1554411_at 0.94
41240001 0.0080 ¡0.30 201533_at 0.54 ¡0.45 0.38
41240101 0.0013 ¡0.45 223679_at 0.67
CSNK1E 22 38795901 0.0361 ¡0.27 202332_at 0.82 0.88 1.53
222015_at 0.44 0.26
225756_at 0.96 0.87 1.38
226858_at 1.51 0.53 0.78
DKK4 8 42234701 0.0104 ¡0.30 206619_at 0.99
42234801 0.0202 ¡0.27
FZD6 8 104311901 0.0402 ¡0.25 203987_at 0.85 2.02 1.07
MYC 8 128746501 0.0239 ¡0.21 202431_s_at 2.15 3.52 1.52 3.13
128748901 0.0034 ¡0.25
PRICKLE1 12 42982701 0.0133 0.45 226065_at ¡0.75
42983001 0.0201 0.43 226069_at ¡0.40 ¡0.33
230708_at ¡0.38
232811_x_at ¡0.13
PSEN1 14 73603901 0.0270 0.34 203460_s_at ¡0.74 ¡0.76 ¡1.20
207782_s_at ¡0.74 ¡0.68 ¡1.06 ¡1.57
226577_at ¡1.03 ¡0.89 ¡1.55
238816_at ¡1.15 ¡2.07
SFRP1 8 41166001 0.0167 0.44 202035_s_at ¡0.36 ¡1.31 ¡1.30 ¡0.14
41166101 0.0001 0.56 202036_s_at ¡2.15 ¡1.83 ¡2.41
41166201 0.0034 0.49 202037_s_at ¡1.80 ¡3.02 ¡1.21
41166301 0.0138 0.27
41166401 0.0013 0.53
41166501 0.0271 0.44
41166601 0.0345 0.39
41166901 0.0420 0.41
Log FC values are indicated only in cases of P< 0.05.
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alterations, including promoter DNA hypermethylation, can be
detected also in CIMP-negative CRCs representing the majority
of sporadic CRCs.4,44 A reliable plasma methylation marker test
with high specificity and sensitivity—such as Epi proColon 2.0
analyzing SEPT9 promoter methylation45—should be based on
systematic DNA methylation alterations identified and detect-
able both in CIMP-negative and CIMP-positive CRCs.
In this study, systematic analysis of DNA methylation of
WNT signaling pathway genes in relation to CRC development
and progression was performed using methyl capture sequenc-
ing (MethylCap-seq) and whole genomic expression microar-
rays. MethylCap-seq can test both promoter and gene body
regions in the entire genome. For comparing previous and our
DNA methylation results, the in silico analysis of Luo et al.28
data, also including adenomas besides CRC and NAT samples,
was performed. Similarly to the work of Luo et al.,28 we com-
pared a group of NAT samples to CRC and adenoma sample
groups, instead of doing a pairwise comparison of CRC and
NAT samples.
When compared to the methylation array, MethylCap-seq
provides a more extensive overview of whole genome methyla-
tion, although its resolution and sensitivity is lower than that of
BeadChip methylation arrays.31 Concerning WNT signaling
genes in our experiments, approximately one third of the sig-
nificant DMRs was represented and could be analyzed on Bead-
Chip array for gene promoters; only »3% of the identified
DMRs for gene body regions was represented. The coexisting
compatible regions in both test systems showed high DNA
methylation similarity between the diagnostic groups, especially
between adenoma and NAT samples (83%). Concordance
Table 6. WNT pathway genes showing inverse relation between DNA methylation and mRNA expression (adenoma vs. NAT).
Gene expression
Gene data DNA methylation LogFC
Gene symbol Chr Start position P-value Db (AD vs. NAT) Affymetrix probe set ID GSE37364 GSE8671 GSE22242
APC 5 112042901 0.0344 0.29 203525_s_at ¡0.83 ¡1.06 ¡1.00
112074301 0.0072 0.39 203526_s_at ¡1.49 ¡1.29 ¡1.72
203527_s_at ¡0.63 ¡0.54
215310_at ¡0.23 ¡0.11
216933_x_at ¡0.12 ¡0.57 ¡0.91
CACYBP 1 174967301 0.0447 ¡0.23 201381_x_at 0.23 0.54
174967501 0.0116 ¡0.25 210691_s_at 0.31 0.74
174967801 0.0009 ¡0.35 211761_s_at 0.49
174967901 0.0003 ¡0.50
174968001 0.0034 ¡0.44
CHP1 15 41524401 0.0155 0.28 207993_s_at ¡0.78 ¡1.65
214665_s_at ¡0.64 ¡0.46
CXXC4 4 105415501 0.0080 ¡0.26 220277_at 0.88 0.62
105415601 0.0265 ¡0.24 229774_at 0.48 0.32
DAAM2 6 39760001 0.0024 0.58 212793_at ¡1.95 ¡1.80 ¡1.28
39760301 0.0281 0.41
FZD1 7 90893001 0.0154 0.34 204451_at ¡1.24 ¡1.20 ¡0.74
204452_s_at ¡0.50 ¡0.29
NFAT5 16 69598901 0.0388 ¡0.24 215092_s_at 2.09
224984_at 0.46
PRICKLE1 12 42982701 0.0005 0.53 226065_at ¡1.22 ¡0.59
42982801 0.0337 0.36 226069_at ¡0.55 ¡0.41 ¡0.99
42983001 0.0046 0.46 230708_at ¡0.56 ¡0.11
42983101 0.0054 0.54
42983201 0.0241 0.37
PRKCB 16 23847601 0.0015 0.59 207957_s_at ¡1.48 ¡1.33 ¡1.24
23847801 0.0292 0.41 209685_s_at ¡1.52 ¡1.55 ¡0.86
227817_at ¡0.71 ¡0.39
230437_s_at 0.01
RUVBL1 3 127843201 0.0334 ¡0.35 201614_s_at 1.35 1.75 0.79
SFRP1 8 41165901 0.0023 0.59 202035_s_at ¡0.29 ¡0.19 ¡1.30
41166001 0.0016 0.59 202036_s_at ¡2.03 ¡1.00 ¡2.35
41166101 0.0004 0.56 202037_s_at ¡1.77 ¡2.23 ¡1.52
41166201 0.0001 0.60 228413_s_at
41166301 0.0065 0.27
SFRP2 4 154709401 0.0122 0.36 223121_s_at ¡5.87
154709501 0.0009 0.59 223122_s_at ¡0.26 ¡5.86
154709601 0.0046 0.55
154709701 0.0001 0.63
154709801 0.0012 0.57
SFRP4 7 37955801 0.0359 0.35 204051_s_at 0.01 ¡3.71
37955901 0.0067 0.49 204052_s_at 0.02 ¡2.65
37956101 0.0219 0.44
TLE3 15 70390701 0.0148 0,29 206472_s_at ¡0.62
212769_at ¡0.56 ¡0.28
212770_at ¡0.59 ¡0.64
228340_at ¡0.71 ¡0,72
 C 4 (PRICKLE1); C 9 (SFRP1); C9 (SFRP2) hypermethylated DMRs see in Supplementary Table 3B. Log FC values are indicated only in cases of P<0.05.
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between CRC and NAT groups was 58%, but only 30% between
CRC and AD. This partial discordance was most probably
related to the difference between our patient cohorts concern-
ing CIMP and MSI or mutation status. Regarding resolution,
the Illumina BeadChip 450K array detects the methylation sta-
tus of a given CpG site, while MethylCap-seq measures the
summation of methylated CpG sites located within the given
100 bp long analysis window.
In our results, promoter methylation changes affected both
canonical (WNT/b-catenin) and noncanonical [planar cell
polarity (PCP) and WNT/Ca2C] WNT signaling pathways. In
CRC samples, significant DMRs were found in 20.63% of the
WNT pathway gene promoters, which was even higher in ade-
noma samples (27.50%). Aberrant promoter methylation was
mainly detected in the canonical WNT (22.3%) and WNT/
Ca2C pathway genes (22.9%) in CRC, but the PCP pathway was
also affected (18.8%). In AD samples, promoter methylation
changes were principally observed in WNT/Ca2C pathway
genes (40%), while high number of DMRs were also found in
canonical and PCP WNT pathways genes (28.1%).
Similarly to our results, promoter hypermethylation of
canonical WNT inhibitory genes, such as SFRP1,11,12
SFRP2,11,13-15 and SOX17,11,24 was detected both in CRC and
adenoma samples. However, in contrast to the findings of Silva
et al.,11 in our study these genes showed elevated promoter
methylation in adenoma samples compared to CRC tissue. In
accordance with our previous bisulfite sequencing findings,18
SFRP1 and SFRP2 promoter methylation in CRC and AD tissue
samples was also detected by MethylCap-seq at the same
regions (Table 9).
Correspondingly to the previous findings,11,17, 19-20 we found
that another known inhibitor of canonical WNT pathway,
DKK2, was significantly hypermethylated in CRC vs. NAT and
AD vs. NAT comparisons. However, our promoter estimation
considering the sequence in the region between 2000 bp
upstream and 1000 bp downstream from the transcription start
site (if the positive DNA strand was the coding strand) identi-
fied ‘active promoter’ in at least one of the 9 analyzed cell lines,
according to the ENCODE ChromHMM results.46 The studied
DMRs in DKK2 promoter were excluded because they were
labeled as ‘poised promoters’ by ENCODE, despite their signifi-
cance (P-value was between 0.00001 and 0.035 in CRC vs.
NAT; P < 0.01 in AD vs. NAT) and high Db-values (0.41–0.72
in CRC vs. NAT and 0.49–0.60 in AD vs. NAT). The lack of
significant changes in mRNA expression data between groups
also supports the tested DKK2 region as an inactive promoter.
Our MethylCap-seq results indicate that promoter DMRs of
APC, AXIN1, AXIN2, and CSNK1 genes may participate in the
impairment/reduction of the APC-Axin-CSNK1-b-catenin
complex leading to the constitutive activation of the canonical
WNT pathway. APC hypermethylation has been already
described in adenoma and CRC tissue and CRC plasma sam-
ples.19,47,48 In accordance with findings of Judson et al.,48
hypermethylation in the active promoter of the APC gene in
adenoma samples was detected in our study as well (Table 6).
Similar alteration appeared in CRC samples, but in a different
Table 7. WNT pathway genes showing inverse relation between DNA methylation and mRNA expression (CRC vs. adenoma).
Gene expression
Gene data DNA methylation LogFC
Gene symbol Chr Start position P-value Db (CRC vs. AD) Affymterix probe set ID GSE37364 GSE22242
AXIN2 17 63554401 0.0294 0.25 222696_at ¡1.14 ¡1.99
224176_s_at ¡0.97 ¡1.04
224498_x_at ¡0.86
CTNNB1 3 41240001 0.0142 ¡0.20 1554411_at 0.97 1.42
41240101 0.0071 ¡0.33 201533_at 0.37 1.30
41240201 0.0330 ¡0.11 223679_at 0.47 0.93
CXXC4 4 105415501 0.0164 0.20 220277_at ¡0.68 ¡0.93
105416801 0.0278 0.21 229774_at ¡0.47 ¡0.90
NFATC1 18 77159401 0.0240 ¡0.40 209664_x_at ¡0.02
77159501 0.0374 ¡0.35 211105_s_at 1.22
77159601 0.0390 ¡0.37
PRICKLE1 12 42983201 0.0242 ¡0.31 226065_at 0.47 1.22
42983301 0.0198 ¡0.27 226069_at 1.58
42984301 0.0191 ¡0.29 230708_at 0.18
42984401 0.0183 ¡0.25
42984501 0.0358 ¡0.20
SFRP2 4 154709901 0.0429 ¡0.35 223121_s_at 1.39 6.09
154710001 0.0484 ¡0.35 223122_s_at 2.12 6.70
154710301 0.0213 ¡0.33
154710801 0.0143 ¡0.34
154711501 0.0267 ¡0.17
154711601 0.0171 ¡0.17
TLE3 15 70390601 0.0341 ¡0.25 206472_s_at 1.02
70390701 0.0356 ¡0.22 212769_at 1.04
212770_at 0.37
VANGL1 1 116185801 0.0122 0.25 219330_at ¡0.48 ¡0.46
229134_at ¡0.42 ¡0.31
229492_at ¡0.55 ¡0.37
229997_at ¡0.36 ¡0.38
Log FC values are indicated only in cases of P < 0.05.
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region upstream to the APC gene, which was considered as a
‘weak promoter’ or ‘enhancer’. Reduced APC mRNA levels on
microarrays indicate silencing by promoter hypermethylation,
which impairs APC tumor suppressor function during colorec-
tal carcinogenesis, besides the frequent APC mutations. DNA
methylation differences in APC promoter and mutation hot
spot regions could not been detected between samples with or
without APC mutations. This supports that APC mutations
and APC promoter hypermethylation are not exclusive factors,
but rather 2 parallel mechanisms leading to the loss of APC
function. We found APC mutations in approximately one third
of the CRC samples, which is below the mutation rate described
Figure 2. Effect of 5-aza-20-deoxycytidine demethylation treatment on colon cancer cell lines. Gene expression data of colon cancer cell lines under 5-aza-20-deoxycyti-
dine demethylation treatment analyzed on Affymetrix HGU133 Plus 2.0 microarrays are shown (GEO accession numbers of gene expression data sets: GSE32323,38
GSE1452642). Demethylation agent treatment reversed (upregulated) mRNA expression of 7 WNT pathway genes showing promoter hypermethylation and downregu-
lated mRNA expression in benign and/or malignant colonic tissue samples, principally in SW480 and HCT116 colorectal adenocarcinoma cell lines in varying degrees. A.
GSE32323 data set B. GSE14526 data set. Samples are shown in columns, selected transcripts are represented in rows. High mRNA expression intensities are marked in
red, low expression levels are shown in green. AZA D 5-aza-20-deoxycytidine.
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by others (75–80%22). However, we only analyzed a limited
region [BLAST: chr5:112,175,118–112,176,026 (Feb. 2009
GRCh37/hg19 Assembly)] with the most prevalent APC muta-
tions. Still, our results were similar to those of Luo et al.28 find-
ing APC mutations in 29.7% of CRC and 27.8% of adenoma
tissue samples using larger sample size and testing longer APC
regions.
Increased promoter methylation of the AXIN2 gene is
thought to be associated with carcinogenesis of MSIC CRC.49
We also detected AXIN2 promoter hypermethylation with
MethylCap-seq both in CRC and adenoma tissues compared to
NAT samples, but the prevalence of DMRs was higher in gene
body regions (25 hypermethylated DMRs, 13 hypomethylated
DMRs). In silico analysis also revealed a remarkable upregula-
tion of AXIN2 mRNA in both disease groups, suggesting the
tumor promoting function of AXIN2,49 especially in MSS CRC
cases.
We also found b-catenin hypomethylation in CRC com-
pared to NAT tissues, which was also detected earlier by others
using Illumina methylation array and in methylation-sensitive
Table 8. Detected mutations in analyzed colonic tissue samples.
Gene symbol Variant cDNA position Amino acid alteration Affected cDNA sequence Annotation Affected samples
APC_1 96:C/T 3871 Q1291stop ATGTAATCAGACG COSM19072 —
APC_1 140:A/- 3915 Frameshift from aa 1306
Truncated protein (length
1366 aa instead of 2843 aa)
ATAGCAGAAATA — —
APC_1 141:G/T 3916 E1306stop ATAGCAGAAATA COSM18760 —
APC_2 31:G/T 3925 E1309stop ATAAAAGAAAAGA COSM18775 MCS_20100810_0008_01_220 (AD)
APC_2 33–37:AAAGA/—– 3927 Frameshift from aa 1309
Truncated protein (length
1311 aa instead of 2843 aa)
ATAAAAGAAAAGATTGG COSM13113 MCS_20100923_0009_01_220 (AD)
MCS_20110203_0011_02_312 (CRC)
MCS_20110000_0023_02_311 (CRC)
APC_2 70:G/T 3964 E1322stop TGTGAGCGAAGTTCC COSM18702 —
APC_2 139:G/T 4033 E1345stop ATCTTCAGAATCA COSM18759 MCS_20100427_0005_01_210 (AD)
APC_3 125:G/T 4135 E1379stop GTTCAGGAGACCCC COSM18834 —
APC_4 111.5:-/T 4241 Frameshift from aa 1415
Truncated protein (length
1421 aa instead of 2843 aa)
GAATGGTAAGTGGCA COSM19703 —
APC_5 67:A/- 4314 Frameshift from aa 1439
Truncated protein (length
1421 aa instead of 2843 aa)
TAAAACACCTCCAC COSM296347 MCS_20110111_0010_01_220 (AD)
APC_5 101:C/T 4348 R1450stop ACCAAGCGAGAAGTA COSM13127 —
APC_6 105:G/A 4479 Silent T1493T GCCACGGAAAGTA SNP rs41115 MCS_20091104_0002_01_220 (AD)
MCS_20100222_0004_01_210 (AD)
MCS_20100610_0006_01_220 (AD)
MCS_20100810_0008_01_220 (AD)
MCS_20100923_0009_01_220 (AD)
MCS_20110310_0012_01_210 (AD)
MCS_20120109_0014_01_211 (AD)
MCS_20120320_0016_01_211 (AD)
MCS_20110203_0011_02_312 (CRC)
MCS_20100610_0006_02_322 (CRC)
MCS_20110111_0010_02_322 (CRC)
MCS_20110310_0012_02_312 (CRC)
MCS_20110000_0023_02_311 (CRC)
CTNNB1_1 123:C/T 47 P16L TGGAACCAGACAGA — —
CTNNB1_2 87:C/T S45F TCCTTCTCTGAGT COSM5667 —
aa: aminoacid
Table 9. Methyl capture and bisulfite sequencing18 data for SFRP1 and SFRP2 promoter regions (overlapping regions).
METHYL
CAPTURE SEQUENCING
BISULFITE
SEQUENCING18
P-value Db value DNA methylation difference
Gene
symbol
Genomic localization
(start) (hg19)
CRC
vs. NAT
AD
vs. NAT
CRC
vs. AD
CRC
vs. NAT
AD
vs. NAT
CRC
vs. AD
Genomic
localization (hg19)
Amplicon
length (bp)
CRC
vs. NAT
AD
vs. NAT
SFRP1 WNT_SFRP1_41166101 0.0001 0.0004 — 0.56 0.56 – chr8:41166121-41166356 235 0.21 0.15
WNT_SFRP1_41166201 0.0034 0.0001 — 0.49 0.60 –
WNT_SFRP1_41166301 0.0138 0.0065 — 0.27 0.27 –
SFRP2 WNT_SFRP2_154709501 0.0203 0.0009 — 0.46 0.59 – chr4:154709513-154709730 217 0.19 0.28
WNT_SFRP2_154709601 — 0.0046 — — 0.55 –
WNT_SFRP2_154709701 0.0218 0.0001 — 0.47 0.63 –
WNT_SFRP2_154710201 0.0254 0.0022 — 0.30 0.33 – chr4:154710290-154710649 359 0.40 0.46
WNT_SFRP2_154710301 — 0.0022 0.0213 — 0.58 ¡0.33
MethylCap-seq analysis of SFRP1 and SFRP2 promoters revealed that all 100 bp-long sequences overlapping with the regions analyzed by bisulfite sequencing showed
elevated DNA methylation level in CRC and adenoma samples compared to NAT samples (P < 0.05). In case of MethylCap-seq, only the significant (P < 0.05) methyla-
tion changes are represented. The 100-bp analysis windows completely overlapping with bisulfite-sequenced regions are marked in bold.
Significant methylation differences in bisulfite sequencing analysis18
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high resolution melting analysis.20 The significantly hypome-
thylated CpG site (41240163, Illumina ID: cg09678212) in the
previous analysis20 is located within WNT_CTNNB1_41240101
100 bp long analysis window in our study. In silico evaluation
of Luo et al.28 Illumina methylation array data also resulted in
significant (P<0.001) hypomethylation of this CpG site in CRC
compared to NAT (Db= -0.20) and adenoma samples
(Db= -0.12). Besides identifying the only b-catenin promoter
hypomethylated CpG site found by the Illumina platform,
our MethylCap-seq analysis revealed significant hypomethyla-
tion in the 300 bp region (WNT_CTNNB1_41239901;
WNT_CTNNB1_41240001 and WNT_CTNNB1_41240101) of
the CTNNB1 gene promoter. Hypomethylation of this region
in CRC compared to NAT and adenoma samples suggests its
contribution to aberrantly elevated intracellular b-catenin level
in colorectal carcinogenesis. Supporting this, significant eleva-
tion of CTNNB1 mRNA levels were observed in CRC com-
pared to normal samples with logFC: 0.38–0.94, along with
increased nuclear translocation of b-catenin protein as a sign of
the activation of the canonical WNT pathway during malignant
transformation. Oncogenic function of canonical WNT path-
way activation is known to occur at early stages of carcinogene-
sis, and can be promoted by DNA methylation alterations from
the precancerous adenoma stage.
The PCP pathway, as a noncanonical WNT signaling, can
play multiple roles in oncogenesis.50 At an early stage, PCP
pathway has a tumor suppressive effect as it can antagonize the
canonical pathway.50 However, during tumor progression, it
can be tumorigenic by promoting tumor cell motility and inva-
sion, angiogenesis induction, and metastatic spreading.50 DNA
methylation changes both in promoters and transcribed regions
of PCP pathway genes were detected at the adenoma stage.
DMRs were observed in FZD2, FZD7, PRICKLE1, and WNT5A
gene promoters, both in adenoma and CRC samples, while pro-
moter hypermethylation on DAAM2 and downregulation of its
mRNA level were typical only in adenoma tissue compared to
NAT samples. Increased FZD2 and WNT5A levels were mea-
sured in cancer cell lines, including CRC and advanced tumors,
and were shown to promote epithelial-mesenchymal transition
and metastasis.50,51 FZD7 can enhance migration and invasion
of CRC mediated by noncanonical WNT signaling.50
PRICKLE1, a disheveled (Dvl) associated protein, may have a
tumor suppressor function by antagonizing Dvl recruitment by
Frizzled.52 It can bind to Dvl3 and facilitate its ubiquitination-
mediated degradation, suggesting that PRICKLE1 is a negative
regulator of WNT/b-catenin pathway.52,53 Promoter hyperme-
thylation of PRICKLE1, found in adenoma and CRC samples
in our methylation study, also support this idea. DAAM2 and
PRICKLE1 seems to be DNA methylation regulated genes as
inverse correlation was found between their promoter hyper-
methylation and reduced mRNA expression.
The noncanonical WNT/Ca2C pathway, which can antago-
nize b-catenin-dependent signaling and stimulate cell migra-
tion,53 was the most affected by promoter methylation
changes in adenomas. This involved the WNT5A (ligand),
FZD1, 2 and 7 (receptors), and downstream elements, such as
PLCB1, PRKCB, and NFAT5 genes in AD samples, whereas
promoter hypermethylation of FZD2, FZD7, PLCB1, and
PRKCB genes was in silico-validated in adenoma samples.28
Hypermethylation of FZD2, FZD7, PLCB1, and WNT5A gene
promoters was also detected in CRC, compared to NAT sam-
ples. However, in many cases it was not accompanied by down-
regulation of mRNA expression. WNT5A has a dual function:
it can act as tumor suppressor or as oncogene in a context-
dependent manner. Depending on the type and level of co-
receptors, it can activate noncanonical or b-catenin-dependent
WNT signaling. Although its promoter was found to be hyper-
methylated both in adenoma and CRC tissues, with only mod-
erate difference in the gene body region, it was probably not a
DNA methylation-regulated gene. The remarkable increase on
its mRNA expression (AD vs. NAT: logFC: 0.65–1.02; CRC vs.
NAT logFC: 1.21–2.58) may be regulated by other mechanisms.
FZD2 and FZD7 genes, which were upregulated in CRC (FZD7
is already in adenomas) may promote migration and metastatic
spreading.51 The connection between methylation and mRNA
expression of these genes was controversial, since both
increased mRNA expression and promoter hypermethylation
were measured in CRC, which was further elevated in adenoma
tissue samples.
An inverse relation was observed between gene expression
and promoter DNA methylation in WNT-related 23 genes.
Among others, APC, CHP1, PRICKLE1, PRKCB, PSEN1, and
SFRP1 genes were identified as methylation-regulated WNT
pathway genes during colorectal normal-adenoma-carcinoma
sequence progression in view of 5-aza-20-deoxycytidine (5-aza)
demethylation treatment data of colon cancer cell lines, specifi-
cally of HCT116 and SW480. SW480 is a MSS, CIMP-negative
colorectal adenocarcinoma cell line54 most similar to the clini-
cal samples analyzed in our MethylCap-seq study. Demethyla-
tion treatment was capable of inducing re-expression of these
genes in CRC cell lines, suggesting a casual relationship
between promoter hypermethylation and expression silencing
of these genes. Restoration of APC, PRKCB, and SFRP1 expres-
sion by 5-aza treatment was also observed earlier in different
colon cancer cell lines.55-57
Despite having detected most of the DMRs in gene body
regions, we discuss these only shortly here because their contri-
bution is not well known or controversial. Approximately 95%
of the analyzed WNT pathway genes showed aberrant gene
body methylation in adenoma and CRC compared to the NAT
samples with »1.5-fold higher number of DMRs in adenomas.
Gene body methylation may positively regulate gene expres-
sion8,9 and can be involved in splicing regulation.8,58 However,
it can also contribute to gene silencing, according to the whole
genomic bisulfite and RNA sequencing data of Lou et al.59 In
the recent study of Wang et al. about the roles of genic methyla-
tion in prostate tumorigenesis, 12 groups of genes with collabo-
rative differential methylation patterns, including hyper-
methylated promoter/hypermethylated gene body and hyper-
methylated promoter/hypomethylated gene body, were identi-
fied, assuming a gene activating role for gene body
methylation.60 In line with these findings, we identified strongly
hypermethylated gene body associated with upregulated
mRNA expression in WNT pathway genes, such as AXIN2,
CSNK1E, MYC, NKD1, which expression was downregulated
after 5-aza-20-deoxycytidine treatment in colon cancer cell
lines. Also, in other genes, reduced expression was associated
with intense gene body hypermethylation reversed by 5-aza
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demethylation agent (e.g., PPARD) in CRC cell lines. Our study
resulted in gene body methylation alterations between CRC and
NAT samples in LRP5, TCF7L1, WNT2, and WNT6 WNT sig-
naling pathway genes, on the same, mainly intronic regions, as
in a previous study by Farkas et al.20
Further research focusing on disease-specific methylation
alterations and gene expression regulatory mechanisms is
required to clarify the selective functions of DNA methylation
at the gene body and other non-promoter regions.59
Conclusions
DNA methylation alterations affect both canonical and nonca-
nonical WNT signaling pathway genes at their promoter and
gene body regions. Using MethylCap-seq, which allows exten-
sive discovery of DNA methylation in the entire genome, we
identified new aberrant methylation patterns affecting genes
including CTNNB1, DAAM2, and PRICKLE1, characterizing
the colorectal normal-adenoma-dysplasia sequence progres-
sion. Previously described methylation changes in WNT path-
way genes during colorectal carcinogenesis, such as SFRP1,
SFRP2, SOX17, and APC, could also be successfully verified.
Our results suggest that DNA methylation changes of
canonical and noncanonical WNT signaling pathways also con-
tribute to the development and progression of CIMP-negative
CRC, besides the frequent APC mutations. Aberrant DNA
methylation already appears in adenomas, indicating DNA
methylation as an early event of colorectal carcinogenesis. The
genomic regions showing epigenetic changes identified in this
study might provide the basis for further studies revealing
potential early diagnostic and therapeutic targets.
Patients and methods
Clinical samples
A total of 30 colonic tissue samples [15 adenoma, 9 CRC, 6 nor-
mal adjacent tissue (NAT)] were included in the MethylCap-
seq study (Table 2, Table 3). All adenoma and part of CRC
samples were collected during screening colonoscopy; further
surgically removed CRC and NAT tissue samples were also
analyzed.
After informed consent of untreated patients, colonic biopsy
samples were taken during endoscopic intervention and stored
in RNALater Stabilization Solution (Ambion, ThermoFisher
Scientific, AM7024) at ¡80C until use. Biopsy samples from
the same site were immediately fixed in buffered formalin for
histological evaluation. Histological diagnoses were established
by experienced pathologists. Tissue samples from untreated
CRC patients were also obtained from surgically removed colon
or rectum tumors and from histologically NAT that originated
from the area farthest available from the tumor. Tissue samples
were snap frozen in liquid nitrogen directly after surgery and
were stored at -80C. Detailed patient specification is described
in Table 2. The study was conducted according to the Helsinki
declaration and approved by the local ethics committee and
government authorities [Regional and Institutional Committee
of Science and Research Ethics (TUKEB) Nr.: 69/2008, 202/
2009 and 23970/2011 Semmelweis University, Budapest,
Hungary].
MSI status was determined according to the results of
immunohistochemical staining as described earlier17 with
monoclonal antibodies for MLH1 (1:80), MSH2 (1:80), MSH6
(1:80), PMS2 (1:150, all from Novocastra/Leica Biosystems
NCL-L-MLH1, NCL-MSH2, NCL-L-MSH6, NCL-L-PMS2)
markers. A tumor sample was scored MSS if all of the 4 above
MMR proteins showed expression.
CIMP category was specified using both classic (CDKN2A,
MLH1, MINT1, MINT2, and MINT31)7,32 and Weisenberger
(CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1) marker
panels,33 according to the MethylCap-seq data overlapping
with regions of CIMP panel methylation-specific PCRs.7,32,33 A
sample was considered as CIMP-positive (CIMP-high) when at
least 2 of the 5 markers (in case of the classic panel) and at least
3 of the 5 markers (in case of the new panel) were found to be
methylated.
DNA isolation
Tissue samples were homogenized in 2% sodium dodecyl sul-
fate, and digested with 4 mg/mL proteinase K for 16 hat 56C.
Genomic DNA was isolated using High Pure PCR Template
Preparation Kit (Roche Applied Science, 11796828001) accord-
ing to the manufacturer’s instructions.17 DNA was eluted in 2x
with 100 ml RNase- and DNase-free water and stored at -20C.
Isolated DNA samples was quantified by Qubit fluorometer
using Qubit dsDNA HS Assay (Invitrogen, ThermoFisher Sci-
entific, Q32854).
Methyl capture sequencing
After fragmentation of 3 mg genomic DNA samples (100–
400 bp) using Bioruptor Sonicator (Diagenode, UCD-300), the
DNA fragments containing methylated CpGs were isolated in
SX-8G IP-Star Compact Automated System using Auto
MethylCap kit (Diagenode, C02020011) using High Elution
Buffer according to the manufacturer’s instructions.61
The methylated DNA fraction was purified on QIAquick
PCR purification columns (Qiagen, 28104). SYBR Green quan-
titative RT-PCR was performed using Human meDNA primer
pair (TSH2B) (Diagenode, pp-1041-500) for detection of
methylated DNA and Human unDNA primer pair (GAPDH)
(Diagenode, pp-1044-500) for showing unmethylated DNA.
Library preparation was carried out using Illumina TruSeq
ChIP Sample Preparation kit (Illumina, IP-202). Cluster gener-
ation was done on cBot instrument using TruSeq SR Cluster
Kit v3-cBot-HS (Illumina, GD-401-3001) which provides
reagents that bind samples to complementary adapter oligos
for cluster amplification on single-read flow cells. Next genera-
tion sequencing of the methylated DNA fragments was per-
formed on HiScanSQ instrument using TruSeq SBS v3-HS
reagents (Illumina, FC-401-3001) according to the manufac-
turer’s instructions. Bowtie262 with default settings was used to
map the 100 bp paired and 50 bp unpaired reads to the hg19
human genome reference assembly.63 The generated bam files
were sorted and indexed by samtools.64 Data were processed by
the MEDIPS65 bioconductor R package. After quality control,
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unpaired reads were extended to the length of the average frag-
ment length of the paired samples (250 bp). PCR duplicates
were removed, then the coverage data were binned with 100 bp
window size. Methylation probabilities (b-values hereafter)
were calculated with respect to genome wide CpG density
dependent Poisson distributions.
In silico DNA methylation analysis of WNT pathway genes
Illumina BeadChip 450K DNA methylation array data sets
from Luo et al.28 were downloaded from NCBI Gene Expres-
sion Database and analyzed (GEO accession number:
GSE48684). This data set contains the methylation results of
120 colorectal tissue samples including CRC, AD, and NAT
samples (Table 3). CpG sites belonging to the significant DMRs
in our MethylCap-sey study were searched on the Illumina
BeadChip 450K array, and P- and Db-values were determined
in CRC vs. NAT, AD vs. NAT and CRC vs. AD comparisons.
Gene expression analysis
Gene expression data of colonic tissue samples from the Gene
Expression Omnibus (GEO) database were included in the in
silico mRNA expression analysis of WNT pathway genes.
WNT pathway genes were selected according to the KEGG
pathway database. GSE37364 set contains Affymetrix HGU133
Plus2.0 whole transcriptome data of 94 colonic biopsy samples
(38 healthy normal, 27 colorectal adenocarcinoma, and 29
tubulovillous/villous adenoma) previously hybridized by our
research group.35 Five GEO data sets made by others on the
same platform were also analyzed (GSE8671,36 GSE18105,37
GSE32323,38 GSE22242,39 GSE934840). Gene expression data of
CRC and healthy normal (N)/ normal adjacent tissue (NAT)
samples are available under serial accession numbers
GSE18105, GSE32323 and GSE9348. GSE8671 data set contains
mRNA expression data of adenoma and healthy normal biopsy
samples, GSE22242 dataset includes transcriptome analysis
results of pooled normal, adenoma, and CRC biopsy samples.
Differentially expressed genes were determined.
Demethylation analysis on colorectal cancer cell lines
Gene expression data of 5-aza-20-deoxycytidine (5-aza)-treated
colorectal cancer cell lines (HT29, COLO320, HCT116, RKO,
SW480) were downloaded and in silico analyzed [GEO acces-
sion numbers: GSE29060 (previously performed by our
research group),41 GSE32323,38 GSE14526,42 and GSE4158843].
GSE29060 and GSE41588 data sets contain the expression data
of HT29 cells treated with 5-aza at higher concentration
(5–10 mM) for 72 hours and 5 days respectively. In another 2
studies (GSE32323 and GSE14526) 5-aza was applied for 72
hours at lower concentrations (0.5 mM and 3 mM, respectively).
Differentially expressed genes after 5-aza demethylation treat-
ment were determined.
Mutation analysis
Mutation hot spot regions of APC and b-catenin genes were
amplified using custom made PCR primers (shown in
Supplementary Table 3) and amplicons were sequenced with a
GS Junior instrument (Roche), as described earlier.66 Briefly,
Rapid Library Molecular Identifier (RL_MID) adaptors were
ligated to the PCR products during library preparation provid-
ing a sample specific sequence motif. The quality checking of
PCR libraries were made on Agilent Bioanalyzer instrument
using High Sensitivity DNA Chip (Agilent, G2939AA, 5067-
4626). Emulsion PCR amplification of the amplicon libraries
was performed using the Lib-L emPCR Kit (Roche,
05996481001), with 2 DNA molecules per bead ratio following
the manufacturer’s instructions. Bead enrichment and sequenc-
ing were carried out using GS Junior Titanium Sequencing Kit
(Roche, 05996554001) according to the method described in
the Sequencing Method Manual, GS FLX Titanium Series.
Amplicon Variant Analyzer software (Roche) was applied for
identification of variants.
Statistical analysis
During statistical evaluation of gene expression and DNA
methylation data of 160 WNT signaling pathway genes, false
discovery rate (FDR) was applied for Student t-test with the cri-
teria P< 0.05 in all paired comparisons. In case of gene expres-
sion for LogFC calculation, the differences between the
averages of samples groups were considered (abs  1 criteria).
Methylation alterations between diagnostic groups were
characterized by Db-values (the differences of the average
b-values of sample groups).
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